Literature DB >> 16013220

Relationships among clinical measures of periodontal disease and their associations with systemic markers.

James D Beck1, Steven Offenbacher.   

Abstract

BACKGROUND: Recent investigations of the relationship between periodontitis and systemic disease require that periodontal disease also must be thought of as a disease process that is an exposure for a systemic disease or condition (outcome), rather than as the outcome itself. When viewing periodontal disease as an exposure, investigators must consider the clinical, microbiological, and inflammatory components of periodontitis that potentially convey risk for the systemic outcome of interest, which may or may not be the same as those associated with the assessments used to define tooth-based disease. Another important consideration is the temporal relationship between the exposure and the outcome of interest.
METHODS: To explore which definitions of periodontal disease or clustering of clinical signs are important with regards to systemic exposure to inflammatory stress, we examined the relationship between clinical periodontal disease measures and 2 systemic inflammatory markers of increased risk for cardiovascular disease: serum soluble intercellular adhesion molecule (sICAM), which is a measure of vascular stress and serum C-reactive protein (CRP), which is a measure of hepatic acute-phase response. The Dental Arteriosclerosis Risk in Communities (ARIC) study, a cross-sectional study of the relationship between periodontal disease and cardiovascular disease, forms the basis for the examples used in this investigation.
RESULTS: Our findings demonstrated that while attachment loss, probing depth, (PD) and bleeding on probing (BOP) are individually associated with sICAM and CRP, only BOP remains significant for sICAM when all 3 are in the model and, for CRP, only PD remains significant. Both of these clinical parameters were more robust in estimating the degree of systemic inflammation than traditional classifications of mild, moderate, and severe periodontitis or other measures of disease severity such as attachment loss.
CONCLUSIONS: When selecting a definition of "systemic periodontitis" (periodontal disease that represents an exposure for a systemic condition), it is helpful to think of periodontal disease as a chronic oral infection with a number of clinical signs, rather than as the dento-centrically defined entity, periodontal disease. Thus, "systemic periodontitis" should be defined predicated upon those clinical signs that best represent the underlying mechanisms and temporal sequence that may affect that systemic outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 16013220     DOI: 10.1902/annals.2002.7.1.79

Source DB:  PubMed          Journal:  Ann Periodontol        ISSN: 1553-0841


  36 in total

1.  Association between γ' fibrinogen levels and inflammation.

Authors:  Kristine S Alexander; Theresa E Madden; David H Farrell
Journal:  Thromb Haemost       Date:  2010-12-21       Impact factor: 5.249

2.  Periodontal diseases and carotid intima-media thickness in Bangladesh.

Authors:  Fen Wu; Yu Chen; Ryan T Demmer; Faruque Parvez; Rina Rani Paul; Ishrat Shaheen; Golam Sarwar; Alauddin Ahmed; Mahbub Eunus; Nafiz Ahsan; Nur Mohammad Habibullah; Tariqul Islam; Tatjana Rundek; Habibul Ahsan; Moise Desvarieux
Journal:  J Clin Periodontol       Date:  2016-08-12       Impact factor: 8.728

3.  Can the relation between tooth loss and chronic disease be explained by socio-economic status? A 24-year follow-up from the population study of women in Gothenburg, Sweden.

Authors:  Claudia Cabrera; Magnus Hakeberg; Margareta Ahlqwist; Hans Wedel; Cecilia Björkelund; Calle Bengtsson; Lauren Lissner
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

4.  Changes in periodontal disease experience from 26 to 32 years of age in a birth cohort.

Authors:  W Murray Thomson; Jonathan M Broadbent; Richie Poulton; James D Beck
Journal:  J Periodontol       Date:  2006-06       Impact factor: 6.993

Review 5.  Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases.

Authors:  Harvey A Schenkein; Bruno G Loos
Journal:  J Clin Periodontol       Date:  2013-04       Impact factor: 8.728

6.  Salivary and serum markers of angiogenesis in periodontitis in relation to smoking.

Authors:  Çiğdem Yılmaz Şaştım; Mervi Gürsoy; Eija Könönen; Akseli Kasurinen; Susanna Norvio; Ulvi Kahraman Gürsoy; Başak Doğan
Journal:  Clin Oral Investig       Date:  2020-07-08       Impact factor: 3.573

7.  A prospective cohort study of periodontal disease measures and cardiovascular disease markers in HIV-infected adults.

Authors:  Lance T Vernon; Denise C Babineau; Catherine A Demko; Michael M Lederman; Xuelei Wang; Zahra Toossi; Aaron Weinberg; Benigno Rodriguez
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-09       Impact factor: 2.205

8.  Results from the Periodontitis and Vascular Events (PAVE) Study: a pilot multicentered, randomized, controlled trial to study effects of periodontal therapy in a secondary prevention model of cardiovascular disease.

Authors:  Steven Offenbacher; James D Beck; Kevin Moss; Luisito Mendoza; David W Paquette; David A Barrow; David J Couper; Dawn D Stewart; Karen L Falkner; Susan P Graham; Sara Grossi; John C Gunsolley; Theresa Madden; Gerardo Maupome; Maurizio Trevisan; Thomas E Van Dyke; Robert J Genco
Journal:  J Periodontol       Date:  2009-02       Impact factor: 6.993

9.  Characterizing traditionally defined periodontal disease in HIV+ adults.

Authors:  Lance T Vernon; Catherine A Demko; Christopher C Whalen; Michael M Lederman; Zahra Toossi; Mianda Wu; Yiping W Han; Aaron Weinberg
Journal:  Community Dent Oral Epidemiol       Date:  2009-07-14       Impact factor: 3.383

10.  Evaluating clinical periodontal measures as surrogates for bacterial exposure: the Oral Infections and Vascular Disease Epidemiology Study (INVEST).

Authors:  Ryan T Demmer; Panos N Papapanou; David R Jacobs; Moïse Desvarieux
Journal:  BMC Med Res Methodol       Date:  2010-01-07       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.